Pharma BD Deal Intelligence

Johnson & Johnson / Kelonia Therapeutics, Inc.

2025 · Co-Development · Complete

Kelonia Therapeutics entered a strategic collaboration with Johnson & Johnson to discover and develop novel in vivo CAR-T cell therapies, applying Kelonia's proprietary iGPS (in vivo Gene Placement System) platform to Johnson & Johnson oncology targets of interest. Kelonia leads early research and platform optimization; Johnson & Johnson contributes development, regulatory and commercialization capabilities. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Johnson & Johnson deals